First patients enrolled in Phase I Hodgkin’s Lymphoma Study

Heidelberg, Germany — November 15, 2010 — Affimed Therapeutics AG, the therapeutic TandAb® antibody company, today announced that the first patients with Hodgkin’s Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study.

The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin’s Lymphoma patients across two centers in Europe and the US. The first patients have now been treated with Affimed’s lead product AFM13 and will receive a total of four doses in weekly intervals. In the initial dosing the antibody was well tolerated. Results from the trial will become available on a patient by patient basis and complete data are expected by Q4 2011.

AFM13 is an innovative tetravalent, bispecific antibody based on Affimed’s proprietary RECRUIT-TandAb® technology. It binds the CD30 target molecule on the surface of Reed- Sternberg tumor cells and simultaneously activates natural killer cells (NK cells). Preclinical data suggests that RECRUIT-TandAbs® are able to identify and selectively destroy tumor cells in the human body. AFM13 has been granted Orphan Drug designation in Europe and the US.

The European and US Phase I study will primarily assess safety, tolerability and the pharmacokinetics of AFM13 plus first indications of biologic activity. Principal investigator in Europe is Prof. Dr. Andreas Engert, Chairman of the German Hodgkin Study Group and professor of internal medicine, hematology, and oncology at The University Hospital of Cologne. Principal investigator in the US is Professor Dr. Anas Younes (Director, Clinical and Translational Research Program, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston).

“With the first TandAb® antibody entering the clinic Affimed has achieved a very important milestone towards the clinical validation of our TandAb® platform”, said Dr. Rolf Günther, CEO of Affimed. “We are very happy that both FDA and the Paul-Ehrlich-Institute supported our IND and CTA application and look forward to advancing the treatment of Hodgkin’s Lymphoma and other cancers by exploiting the unique advantages of our technology.”

Professor Dr. Melvyn Little, CSO of Affimed added: “The application of tetravalent, bispecific antibodies to treat cancer is a first in humans and has the potential to create new and exciting treatment options for a wide range of diseases. TandAbs® are expected to have major advantages over first generation antibodies. Advanced Hodgkin’s Lymphoma is a severe disease and there are only few treatment options available or in development.”

About Affimed:

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical need. The company has been generating a growing pipeline of anticancer drug candidates based on its proprietary TandAb® technology platform. Affimed’s lead product candidate AFM13 for the treatment of Hodgkin’s disease is in phase I clinical development. Both AFM11 and AFM15 to treat Non-Hodgkin’s lymphoma and autoimmune diseases, respectively, are currently in preclinical development. Further novel product candidates are being developed for the treatment of solid tumors, autoimmune diseases and asthma. Affimed’s proprietary and highly productive TandAb® technology enables the company to generate unique tetravalent, bispecific, fully human antibody formats that promise increased therapeutic potential and superior profiles compared to monoclonal antibodies. The private company Affimed, which employs 27 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg.

About TandAbs®:

TandAbs®, which were invented and developed by Affimed scientists, are tetravalent bispecific antibody formats that have two binding sites for each antigen. They bind to target molecules on the surface of, for example, tumor cells and can activate immune effector cells like cytotoxic T-cells or natural killer (NK) cells. TandAbs® possess the same avidity and affinity for each target as an IgG. Combined with their bispecificity, this format represents a potent further development of therapeutic monoclonal antibodies and, potentially, a superior alternative to first generation antibody formats/scaffolds. A robust production process for AFM13 has been established with excellent stability of the drug product. Affimed has developed different kinds of TandAbs® for specific indications. While RECRUIT-TandAbs® are applied to oncology, BiBLOCK- and PROLONG-TandAbs® are developed for the treatment of autoimmune and inflammatory diseases.

About Hodgkin’s Lymphoma:

Hodgkin’s Lymphoma is a malignant type of cancer targeting the lymphatic system, with the highest incidence among those aged between 20-40 years, and over 70 years. According to estimates by the American Cancer Society, Hodgkin’s Lymphoma has a yearly incidence of about 8,500 patients in the US alone. Despite the strong potential for recovery at the early stage of the disease, only insufficient therapeutic approaches have so far been developed, particularly with regard to those patients who do not respond to aggressive chemo- and radiotherapy, or those who relapse. Due to the severe side effects and the toxicity of this combined chemo- and radiotherapy, there is a great medical need for new treatments.